EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
In this podcast, Xiuning Le from the University of Texas MD Anderson Cancer Center, Houston, TX, Eric Nadler from the Baylor University Medical Center, Dallas, TX, Daniel Costa from the Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, and John Heymach from the University of Texas MD Anderson Cancer Center, Houston, TX discuss the use of EGFR tyrosine kinase inhibitors for the treatment of metastatic non-small cell lung cancer harboring uncommon EGFR mutations. This podcast is published open access in Targeted Oncology and is fully citeable. You can access the original published podcast article through the Targeted Oncology...